248 related articles for article (PubMed ID: 20647770)
1. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
Liles JS; Arnoletti JP; Tzeng CW; Howard JH; Kossenkov AV; Kulesza P; Heslin MJ; Frolov A
Cancer Biol Ther; 2010 Sep; 10(6):555-63. PubMed ID: 20647770
[TBL] [Abstract][Full Text] [Related]
2. ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?
Landgraf R
Cancer Biol Ther; 2010 Sep; 10(6):564-6. PubMed ID: 20676043
[No Abstract] [Full Text] [Related]
3. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
5. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
Liles JS; Arnoletti JP; Kossenkov AV; Mikhaylina A; Frost AR; Kulesza P; Heslin MJ; Frolov A
Br J Cancer; 2011 Aug; 105(4):523-33. PubMed ID: 21792199
[TBL] [Abstract][Full Text] [Related]
6. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Noto A; De Vitis C; Roscilli G; Fattore L; Malpicci D; Marra E; Luberto L; D'Andrilli A; Coluccia P; Giovagnoli MR; Normanno N; Ruco L; Aurisicchio L; Mancini R; Ciliberto G
Oncotarget; 2013 Aug; 4(8):1253-65. PubMed ID: 23896512
[TBL] [Abstract][Full Text] [Related]
8. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
9. ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.
Lee H; Lee H; Chin H; Kim K; Lee D
Oncotarget; 2014 Jul; 5(13):5138-52. PubMed ID: 24970817
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
11. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation.
Hao J; Yang X; Ding XL; Guo LM; Zhu CH; Ji W; Zhou T; Wu XZ
Sci Rep; 2016 Sep; 6():32809. PubMed ID: 27609096
[TBL] [Abstract][Full Text] [Related]
12. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Buck E; Eyzaguirre A; Haley JD; Gibson NW; Cagnoni P; Iwata KK
Mol Cancer Ther; 2006 Aug; 5(8):2051-9. PubMed ID: 16928826
[TBL] [Abstract][Full Text] [Related]
14. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
15. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
16. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Zhu S; Belkhiri A; El-Rifai W
Gastroenterology; 2011 Nov; 141(5):1738-48.e1-2. PubMed ID: 21741919
[TBL] [Abstract][Full Text] [Related]
17. PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug.
Wang C; Yang A; Zhang B; Yin Q; Huang H; Chen M; Xie J
Pancreas; 2014 Mar; 43(2):291-7. PubMed ID: 24518510
[TBL] [Abstract][Full Text] [Related]
18. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
19. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Conradt L; Godl K; Schaab C; Tebbe A; Eser S; Diersch S; Michalski CW; Kleeff J; Schnieke A; Schmid RM; Saur D; Schneider G
Neoplasia; 2011 Nov; 13(11):1026-34. PubMed ID: 22131878
[TBL] [Abstract][Full Text] [Related]
20. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Song X; Fan PD; Bantikassegn A; Guha U; Threadgill DW; Varmus H; Politi K
Cancer Res; 2015 Mar; 75(6):1035-45. PubMed ID: 25596284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
